Deborah Katz, MD
Hematology · Chicago, ILNPI 1396901500
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Stemline Therapeutics Inc. at 53.6% of the total. Reporting peaked in 2019 at $19,191 and has fallen 99.5% since, to $95 in 2025.
Across 27 payments — averaging $1419.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$21K
- AbbVie$9K
- Rigel Pharmaceuticals, Inc.$3K
- Sanofi$2K
- Amgen$2K
- Dova Pharmaceuticals$1K
- plus $95 from 1 others
Across 100 payments — averaging $32,914 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$2.7M
- Seagen Inc.$350K
- AbbVie$83K
- Genentech, Inc.$42K
- Astellas Pharma Global Development$38K
- Morphosys AG$31K
- plus $3K from 3 others
What the payments were for
- Consulting fees$14,64638%
- Speaking & faculty fees$20,79054%
- Travel & lodging$2,2676%
- Food & beverage$5191%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stemline Therapeutics Inc. | 18 | $20,541 |
| AbbVie | 2 | $9,000 |
| Rigel Pharmaceuticals, Inc. | 1 | $2,740 |
| Sanofi | 2 | $2,448 |
| Amgen | 1 | $2,093 |
| Dova Pharmaceuticals | 2 | $1,400 |
| Sobi, Inc | 1 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,317 in reported general payments places this provider in the 75th percentile of 49 hematology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 23 | $419,005 |
| PomalystPomalidomide | 11 | $235,696 |
| EliquisApixaban | 12 | $6,757 |
| Acyclovir | 86 | $897 |
| Dexamethasone | 30 | $502 |
| Hydroxyurea | 42 | $423 |
| Allopurinol | 21 | $132 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 30 | $128 |
| Famotidine | 11 | $128 |
| Omeprazole | 21 | $101 |
| Prednisone | 20 | $85 |
| Levofloxacin | 12 | $71 |
| Ondansetron Hcl | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other hematology in Chicago
- Jayesh MehtaChicago$183K
- Celalettin UstunChicago$153K
- Kunal DesaiChicago$150K
- John QuigleyChicago$132K
- Parameswa VenugopalChicago$122K
- Nadia KhanChicago$66K
- Seema SinghalChicago$65K
- Olga FrankfurtChicago$49K
- Martin TallmanChicago$28K
- Robert SteinChicago$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.